Latest Breaking News On - After sandoz - Page 1 : comparemela.com

By Syndicated Content By Andrew Chung (Reuters) – The U.S. Supreme Court on Monday dashed Novartis AG’s hopes of launching a generic version of Amgen Inc’s multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company’s challenge to two patents on the drug. The justices turned away Novartis subsidiary Sandoz Inc’s appeal of a lower court decision that upheld the validity of the patents. Enbrel, a biologic also known as etanercept used to treat adults with moderate to severe active rheumatoid arthritis, is Amgen’s top-selling drug, accounting for nearly $5 billion of the company’s $24.2 billion in product sales for 2020. Enbrel was launched in 1998 by Immunex Corp, which Amgen acquired in 2002.

New yorkUnited statesAndrew chungImmunex corpSandoz incUs courtUs supreme court onAmgen incAfter sandozFederal circuitWill dunhamபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்ஆண்ட்ரூ சுங்சாண்டோஸ் இன்க்எங்களுக்கு நீதிமன்றம்